阿霉素全球市场 - 市场规模、份额、成长分析：按类型 - 产业预测（2023-2030 年）

Global Doxorubicin Market Size, Share, Growth Analysis, By Type(Conventional Doxorubicin formulation and liposomal Doxorubicin formulations) - Industry Forecast 2023-2030

出版日期: 2023年10月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计2021年全球阿霉素市场规模为9亿美元，2022年将达11亿美元。该市场预计到 2030 年将达到 17 亿美元，在预测期内（2023-2030 年）年复合成长率为 5.8%。

全球阿霉素市场正在经历显着成长，预计将继续保持上升趋势。阿霉素是一种广泛使用的化疗药物，用于治疗多种癌症，主要是卵巢、卵巢癌、肺癌和软组织肉瘤。该市场是由全球癌症罹患率不断上升以及对有效癌症治疗方案不断增长的需求所推动的。此外，药物输送系统和联合治疗的进步进一步推动了市场的成长。然而，它也面临着治疗费用急剧上升、药物副作用的可能性以及替代疗法出现等挑战。儘管存在这些挑战，由于对个人化医疗和标靶治疗的日益关注，阿霉素市场预计将在未来年度产生利润丰厚的机会。

全球阿霉素市场的驱动因素之一是全球癌症盛行率的不断上升。阿霉素是一种化疗药物，广泛用于治疗多种癌症，包括乳癌、肺癌和白血病。癌症罹患率的上升和对有效癌症治疗的需求不断增长正在推动对阿霉素的需求。此外，探索阿霉素新适应症和配方的持续研究和开发也有助于市场成长。

全球阿霉素市场的抑制因素之一是其使用可能产生的副作用。已知阿霉素会引起各种副作用，包括心臟毒性、骨髓抑制和胃肠道疾病。这些副作用会限制其使用并对药物给药提出挑战。医疗保健提供者应密切监测给药阿霉素的患者，并采取必要的预防措施，以尽量减少和控制这些副作用。此外，在某些情况下，替代治疗方案和标靶治疗的出现也可能影响对阿霉素的需求。

该报告研究了全球多柔比星市场，并提供了市场概述，包括按类型、地区和参与市场的公司概况分類的趋势。

主要企业简介
- Pfizer
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Aspen Pharmacare Holdings Limited
- Baxter International Inc.
- Mylan NV
- Dr. Reddy's Laboratories Ltd.
- Cipla Limited
- Accord Healthcare Ltd
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Zydus Cadila
- Actavis Generics
- Wockhardt Ltd.
- Sandoz International GmbH

简介目录

Product Code: SQMIG35A2310

Global Doxorubicin Market size was valued at USD 0.9 billion in 2021 and is poised to grow from USD 1.1 billion in 2022 to USD 1.7 billion by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

The global doxorubicin market is experiencing significant growth and is expected to continue its upward trajectory in the coming years. Doxorubicin is a widely used chemotherapy drug that is primarily used in the treatment of various types of cancers, including breast cancer, ovarian cancer, lung cancer, and soft tissue sarcomas. The market is driven by the increasing prevalence of cancer worldwide and the growing demand for effective cancer treatment options. Additionally, advancements in drug delivery systems and combination therapies are further fueling the market growth. However, the market is also faced with challenges such as the high cost of treatment, potential side effects of the drug, and the emergence of alternative therapies. Despite these challenges, the increasing focus on personalized medicine and targeted therapies is expected to create lucrative opportunities for the Doxorubicin market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Doxorubicin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Doxorubicin Market Segmental Analysis

The global doxorubicin market is segmented by type and region. Based on type, the market can be segmented into conventional doxorubicin formulation and liposomal doxorubicin formulations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Doxorubicin Market

Increasing Prevalence Of Cancer Worldwide

One driver of the global doxorubicin market is the increasing prevalence of cancer worldwide. Doxorubicin is a widely used chemotherapy drug for the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. The rising incidence of cancer cases, coupled with the growing need for effective cancer treatments, drives the demand for Doxorubicin. Additionally, ongoing research and development activities to explore new indications and formulations of Doxorubicin contribute to market growth.

Restraints in the Global Doxorubicin Market

Potential Side Effects Associated With Its Use

One restraint of the global doxorubicin market is the potential side effects associated with its use. Doxorubicin is known to cause various adverse effects, including cardiotoxicity, myelosuppression, and gastrointestinal issues. These side effects can limit its use and pose challenges in the administration of the drug. Healthcare providers need to carefully monitor patients receiving Doxorubicin and take necessary precautions to minimize and manage these side effects. Furthermore, the availability of alternative treatment options and the emergence of targeted therapies may also impact the demand for Doxorubicin in certain cases.

Market Trends of the Global Doxorubicin Key

One key market trend in the global doxorubicin market is the increasing adoption of combination therapies. Doxorubicin, a widely used chemotherapy drug, is often used in combination with other drugs or treatment modalities to enhance its effectiveness and reduce potential side effects. Combination therapies can help to overcome drug resistance, improve response rates, and increase overall survival rates for patients. Healthcare providers and researchers are exploring various combination regimens involving Doxorubicin, such as combining it with targeted therapies or immunotherapies, to achieve better treatment outcomes. This trend highlights the ongoing efforts to optimize Doxorubicin's therapeutic potential and improve the overall management of cancer patients.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Doxorubicin Market by Type
- Market Overview
- Conventional Doxorubicin formulation and liposomal Doxorubicin formulations
Global Doxorubicin Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Aspen Pharmacare Holdings Limited (South Africa)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Baxter International Inc. (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mylan N.V. (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Dr. Reddy's Laboratories Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Cipla Limited (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Accord Healthcare Ltd. (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Hikma Pharmaceuticals PLC (Jordan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Fresenius Kabi AG (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Kyowa Kirin Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Zydus Cadila (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Actavis Generics (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Wockhardt Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sandoz International GmbH (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments